Skip to main content

Bladder Mucosa Graft

A bladder mucosa graft transfers living urothelium with its supporting mucosal tissue. It differs from a vascularized bladder flap and from an acellular bladder matrix. It has historical urethral applications and a limited reconstructive role in selected fistulas or congenital defects. For substitution urethroplasty, the AUA favors oral mucosa as the first-choice graft by expert opinion; the separate strong Grade A recommendation concerns buccal versus lingual mucosa as alternatives.[1][2][3][4]

Bladder mucosal grafts have produced favorable results in small, uncontrolled VVF series, mostly from the 1990s–2000s. These reports do not establish a preferred modern repair, superiority over vascularized interposition, or a reliable success percentage for radiation-associated fistula.[5][6][7][8]

See Grafts in GU Reconstruction for general selection principles.

Historical Context​

Pediatric series used bladder mucosa when local tissue was inadequate after failed hypospadias repair, in exstrophy/epispadias, or for acquired urethral strictures. Long-term experience exposed an important distinction: an eventual usable urethra could require several additional operations. Oral mucosa has become the preferred urethral graft; bladder harvest adds another operative site and requires a suitable bladder.[1][2][3][4]

Properties of Bladder Mucosa as a Graft​

PropertyClinical interpretation
Urinary epitheliumAdaptation to urine does not guarantee graft survival, resistance to contracture or normal urethral function.
RevascularizationRabbit studies found similar angiogenic activity for bladder and buccal mucosa; a histological surrogate is not proof of equivalent human outcomes.[9]
ContractionA small canine study found 20–40% shrinkage for bladder mucosa and skin versus under 10% for buccal mucosa. These are experimental observations, not expected human contraction percentages.[10]
HarvestRequires access to healthy bladder mucosa, often through cystotomy. Additional morbidity matters especially when the bladder would not otherwise be opened.
Donor defectSome reported techniques allowed the mucosal donor site to re-epithelialize. This does not eliminate bleeding, leakage, pain or catheter-related concerns.[7]

Clinical Applications​

1. Vesicovaginal Fistula (VVF) Repair​

ReportPopulationOutcome and follow-upImportant limitation
Brandt 1998[5]80 women after gynecologic surgery for benign disease96.3% reported success; repairs within 1–3 months of fistula development15 years describes the treatment experience, not 15-year follow-up for each woman. Not a radiation cohort.
Ostad 1998[7]Six high, large, multiple or recurrent fistulasAll dry at 2–6 years; one irradiated patient needed drainage to six weeksOne irradiated case cannot establish radiation-specific efficacy.
Sharifi-Aghdas 2002[8]14 complicated fistulas; 12 previously repaired13 remained dry at 3–15 monthsTwo stress-incontinence cases and three UTIs were also reported. Closure and continence must be distinguished.
Vyas 2005[6]22 women, including five with previous repair20/22 continent at 3–12 monthsBoth failures had two prior repairs; short, uncontrolled follow-up.

The operations were not identical. Ostad described a mucosal overlay after tract debridement without separately closing the vaginal or bladder defects. Vyas closed the vaginal layer before applying the graft. These descriptions should not be merged into a universal three-step repair. A free graft requires a supportive vascular bed and does not bring the blood supply of a pedicled flap.[6][7]

A graft can be tailored around a difficult location, but proximity to a ureteric orifice requires careful assessment of ureteral integrity. The small Vyas series does not prove a general advantage over Martius/peritoneal flaps or remove the need for reimplantation when the ureter is injured or obstructed. Use the VVF clinical pathway for repair selection and tissue readiness.

2. Urethral Reconstruction — Historical, Largely Supplanted​

  • Kinkead 1994: among 95 patients aged 1–21 years, 81 (85%) eventually achieved a good functional/cosmetic result, but 63 (66%) needed additional procedures, a mean of 2.7 among those reoperated. Follow-up averaged 3.4 years, not decades. Meatal problems occurred in 68% with a terminal circumferential bladder-mucosa segment versus 12% with an onlay patch and 36% with a combined repair.[2]
  • Monfort 1992: seven children had successful onlay/patch repairs; the eighth had a tubular graft and required dilation for secondary stenosis.[1]
  • Decter 1988: 13 boys received 15 graft repairs. Only four initially had a satisfactory result without the reported complications; two ultimately required graft replacement for severe stricture.[3]

Avoid presenting bladder mucosa as a routine first-line urethral graft or promising that an onlay eliminates recurrence. The historical terminal-meatus complication rate does not apply to every reconstructive configuration.

3. Vaginoplasty for Congenital Anomalies​

Chiaramonte described one child with a urogenital sinus who underwent bladder-mucosal vaginoplasty at 20 months and was followed to age 18. The report found no introital stenosis and squamous epithelium on later biopsy. This demonstrates a possible option in a particular congenital anatomy; it does not establish adult sexual outcomes, comparative superiority, or freedom from malignancy. It should not be generalized to routine congenital or gender-affirming vaginoplasty.[11]

4. Ureteral Reconstruction — Experimental and Historical​

Greenberg and Yifeng reported canine bladder-mucosal graft experiments, with encouraging patency or histology. These are not contemporary comparative human data. Modern oral-graft and appendiceal reconstruction have a different evidence base; do not transfer their outcomes to bladder mucosa.[12][13][14]

5. Acellular Bladder Matrix — A Different Material​

Removing the cells creates a scaffold for host ingrowth, not a living mucosal autograft. In the small El-Kassaby urethral study, reported matrix patency was 8/9 in healthy beds and 2/6 in unhealthy beds, compared with 10/10 and 5/5 for buccal grafts. This does not establish equivalence in the healthy subgroup.[15]

Bladder augmentation work with cell-seeded matrices and UROGRAFT remains preclinical. The 2022 porcine scaffold study had four deaths among ten animals, involving scaffold failure, anastomotic dehiscence or catheter obstruction. Promising regeneration must be considered together with these failures. Neither this study, the rat experiments nor the 2025 composite work establishes a routine replacement for enterocystoplasty.[16][17][18]

See Tissue-Engineered Grafts & Bioscaffolds for guideline restrictions and human evidence.

Bladder Mucosa vs Buccal Mucosa​

Oral mucosa has an established urethral role and usually avoids entering the bladder, although oral harvest can cause persistent morbidity. Tissue type alone does not determine success.[4]

In El-Sherbiny's 24-dog experiment, strictures occurred in 8/12 tubular repairs versus 1/12 onlay repairs. Rounded graft-specific rates were 12% buccal, 37% bladder and 62% skin, but the between-material comparison was not statistically significant. These results should not be presented as comparative human failure rates.[10]

Lu's porcine bladder-implant experiment found urothelial marker expression in oral grafts over time while oral epithelial markers persisted. It does not show that human urethral oral grafts uniformly become urothelium. Filipas compared buccal mucosa with full skin, not bladder mucosa; that study cannot support a claim of more inflammation in bladder grafts than buccal grafts.[19][20]

Complications and Concerns​

Potential problems include donor-site morbidity, contracture, stricture, mucosal prolapse, fistula and repeat procedures. Evaluate the native bladder's condition, prior surgery, available mucosa and capacity before considering harvest. An augmented or neurogenic bladder is not a single universal contraindication; the actual donor anatomy and risks matter.

DeRosa reported squamous cell carcinoma 22 years after childhood bladder-mucosal hypospadias repair. A single case does not establish causation, incidence or an evidence-based schedule for routine cancer screening. Long-term reconstructive follow-up and evaluation of new bleeding, obstruction or a suspicious lesion are appropriate; do not promise that any graft is free of later neoplastic risk.[21]

Current Role and When to Choose Bladder Mucosa​

Consider it only within a specific reconstructive plan when established alternatives are unsuitable and the donor bladder and recipient bed are appropriate. Historical VVF and pediatric reports inform the discussion; they do not prove that bladder mucosa is preferred for irradiated tissue or for all salvage cases. For routine urethral substitution, oral mucosa remains the guideline-preferred graft.[4]

See Also​

References​

1. Monfort G, Bretheau D, Di Benedetto V, Bankole R. Urethral stricture in children: treatment by urethroplasty with bladder mucosa graft. J Urol. 1992;148(5):1504–6. doi:10.1016/s0022-5347(17)36950-1

2. Kinkead TM, Borzi PA, Duffy PG, Ransley PG. Long-term followup of bladder mucosa graft for male urethral reconstruction. J Urol. 1994;151(4):1056–8. doi:10.1016/s0022-5347(17)35179-0

3. Decter RM, Roth DR, Gonzales ET. Hypospadias repair by bladder mucosal graft: an initial report. J Urol. 1988;140(5 Pt 2):1256–8. doi:10.1016/s0022-5347(17)42018-0

4. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. Urethral stricture disease guideline amendment (2023). J Urol. 2023;210(1):64–71. doi:10.1097/JU.0000000000003482

5. Brandt FT, Lorenzato FR, Albuquerque CD. Treatment of vesicovaginal fistula by bladder mucosa autograft technique. J Am Coll Surg. 1998;186(6):645–8. doi:10.1016/s1072-7515(98)00129-x

6. Vyas N, Nandi PR, Mahmood M, et al. Bladder mucosal autografts for repair of vesicovaginal fistula. BJOG. 2005;112(1):112–4. doi:10.1111/j.1471-0528.2004.00316.x

7. Ostad M, Uzzo RG, Coleman J, Young GP. Use of a free bladder mucosal graft for simple repair of vesicovaginal fistulae. Urology. 1998;52(1):123–6. doi:10.1016/s0090-4295(98)00120-4

8. Sharifi-Aghdas F, Ghaderian N, Payvand A. Free bladder mucosal autograft in the treatment of complicated vesicovaginal fistula. BJU Int. 2002;89 Suppl 1:54–6. doi:10.1046/j.1464-4096.2001.01728.x

9. Gardikis S, Giatromanolaki A, Ypsilantis P, et al. Comparison of angiogenic activities after urethral reconstruction using free grafts in rabbits. Eur Urol. 2005;47(3):417–21. doi:10.1016/j.eururo.2004.10.014

10. El-Sherbiny MT, Abol-Enein H, Dawaba MS, Ghoneim MA. Treatment of urethral defects: skin, buccal or bladder mucosa, tube or patch? An experimental study in dogs. J Urol. 2002;167(5):2225–8. PubMed.

11. Chiaramonte C, Vestri E, Tripi F, et al. Bladder mucosal graft vaginoplasty: a case report. J Pediatr Adolesc Gynecol. 2018;31(5):528–32. doi:10.1016/j.jpag.2018.06.003

12. Greenberg R, Coleman JW, Quiguyan CC, et al. Bladder mucosal grafts: experimental use as a ureteral substitute and observation of certain physical properties. J Urol. 1983;129(3):634–6. doi:10.1016/s0022-5347(17)52268-5

13. Yifeng J, Shujie X, Hongbin S, et al. Use of free peritoneal and bladder mucosal grafts as ureteral mucosa substitutes for management of avulsion of the ureteral mucosa in a dog model. J Endourol. 2008;22(4):729–34. doi:10.1089/end.2007.0136

14. Bello D, Van Shufflin M, Hofer MD. Expanding the armamentarium: perspectives on buccal mucosal grafts and appendiceal flaps in ureteral reconstructive surgery. J Clin Med. 2025;14(21):7681. doi:10.3390/jcm14217681

15. el-Kassaby A, AbouShwareb T, Atala A. Randomized comparative study between buccal mucosal and acellular bladder matrix grafts in complex anterior urethral strictures. J Urol. 2008;179(4):1432–6. doi:10.1016/j.juro.2007.11.101

16. Pokrywczynska M, Jundzill A, Tworkiewicz J, et al. Urinary bladder augmentation with acellular biologic scaffold — a preclinical study in a large animal model. J Biomed Mater Res B Appl Biomater. 2022;110(2):438–49. doi:10.1002/jbm.b.34920

17. Coutu DL, Mahfouz W, Loutochin O, Galipeau J, Corcos J. Tissue engineering of rat bladder using marrow-derived mesenchymal stem cells and bladder acellular matrix. PLoS One. 2014;9(12):e111966. doi:10.1371/journal.pone.0111966

18. Pokrywczynska M, Fekner Z, Balcerczyk D, et al. Development of UROGRAFT: a bladder acellular matrix-based composite for advanced cystoplasty, highlighting the role of graft shape and composition. ACS Biomater Sci Eng. 2025;published online. doi:10.1021/acsbiomaterials.5c00700

19. Lu M, Zhou G, Liu W, et al. Remodeling of buccal mucosa by bladder microenvironment. Urology. 2010;75(6):1514.e7–14. doi:10.1016/j.urology.2009.12.060

20. Filipas D, Fisch M, Fichtner J, et al. The histology and immunohistochemistry of free buccal mucosa and full-skin grafts after exposure to urine. BJU Int. 1999;84(1):108–11. doi:10.1046/j.1464-410x.1999.00079.x

21. DeRosa R, Stackhouse DA, McMann LP, Sterbis JR. Penile squamous cell carcinoma after a childhood hypospadias repair with bladder mucosa graft. Urology. 2015;85(6):1471–3. doi:10.1016/j.urology.2015.02.021